- Home
- PRME vs DRUG Comparison
PRME vs DRUG Comparison
Compare PRME & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- DRUG
- Stock Information
- Founded
- PRME 2019
- DRUG 2019
- Country
- PRME United States
- DRUG United States
- Employees
- PRME N/A
- DRUG N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- DRUG Pharmaceuticals and Biotechnology
- Sector
- PRME Health Care
- DRUG Health Care
- Exchange
- PRME Nasdaq
- DRUG Nasdaq
- Market Cap
- PRME 191.7M
- DRUG 199.7M
- IPO Year
- PRME 2022
- DRUG N/A
- Fundamental
- Price
- PRME $2.71
- DRUG $26.58
- Analyst Decision
- PRME Buy
- DRUG Strong Buy
- Analyst Count
- PRME 6
- DRUG 6
- Target Price
- PRME $9.38
- DRUG $83.25
- AVG Volume (30 Days)
- PRME 3.3M
- DRUG 51.7K
- Earning Date
- PRME 08-04-2025
- DRUG 08-13-2025
- Dividend Yield
- PRME N/A
- DRUG N/A
- EPS Growth
- PRME N/A
- DRUG N/A
- EPS
- PRME N/A
- DRUG N/A
- Revenue
- PRME $3,846,000.00
- DRUG N/A
- Revenue This Year
- PRME $104.12
- DRUG N/A
- Revenue Next Year
- PRME $196.78
- DRUG N/A
- P/E Ratio
- PRME N/A
- DRUG N/A
- Revenue Growth
- PRME 550.76
- DRUG N/A
- 52 Week Low
- PRME $1.11
- DRUG $0.93
- 52 Week High
- PRME $6.75
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- PRME 69.76
- DRUG 45.82
- Support Level
- PRME $1.56
- DRUG $23.18
- Resistance Level
- PRME $2.78
- DRUG $26.86
- Average True Range (ATR)
- PRME 0.26
- DRUG 1.75
- MACD
- PRME 0.08
- DRUG -0.06
- Stochastic Oscillator
- PRME 76.81
- DRUG 55.14
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.